### ðŸ«  Coronary Artery Disease: Medical Therapy After Percutaneous Coronary Intervention

#### âœ… True Statements
1. Following **percutaneous coronary intervention (PCI)** for **acute coronary syndrome (ACS)**, all patients should receive **aspirin**, a **P2Y12 inhibitor**, and a **high-intensity statin**.
2. **Dual antiplatelet therapy (DAPT)** with **aspirin and a P2Y12 inhibitor** is recommended for **1 year** following PCI for ACS, followed by **lifelong aspirin monotherapy**.
3. **High-intensity statin therapy** is recommended for all patients with **acute coronary syndrome** to reduce cardiovascular risk.
4. **Î²-Blockers** are most strongly indicated for patients with **residual angina** or **left ventricular dysfunction** after ACS.
5. **Angiotensin-converting enzyme (ACE) inhibitors** or **angiotensin receptor blockers (ARBs)** are indicated in patients with **diabetes mellitus** and/or **reduced left ventricular function** following ACS.
6. **Aldosterone antagonists** such as **spironolactone** or **eplerenone** are recommended only in patients with **nonâ€“ST-elevation ACS**, **ejection fraction â‰¤40%**, and either **heart failure** or **diabetes**, who are already receiving an **ACE inhibitor** and **Î²-blocker**.
7. **Calcium channel blockers**, such as **amlodipine** and **diltiazem**, are used in patients with **contraindications to Î²-blockers** or **continued angina** despite optimal therapy, but are not indicated in asymptomatic, normotensive patients.
8. **Immediate-release nifedipine** is contraindicated in **coronary artery disease** due to an association with **increased mortality**.
9. In patients with **myocardial infarction**, a **P2Y12 inhibitor** should be continued for **at least 1 year**, regardless of **stent placement** or **type of stent**.
10. **Ticagrelor** has demonstrated **modest benefit** over **clopidogrel** in ACS patients, based on the **PLATO trial**.
11. **Prasugrel** may be superior to **clopidogrel** but is associated with **higher bleeding risk**.

#### ðŸ’¬ Extra
1. The patient in the vignette is already receiving **aspirin, clopidogrel, and atorvastatin**, which aligns with guideline-directed therapy post-PCI for ACS.
2. After 1 year of DAPT, patients typically continue with **aspirin monotherapy** for secondary prevention.
6. Aldosterone antagonists are **not indicated** in patients with **preserved left ventricular function**.
7. The patient has **no angina** and is **normotensive**, which makes **calcium channel blockers** unnecessary.
10. The **PLATO trial** compared **ticagrelor** and **clopidogrel**, showing a **modest reduction in major adverse cardiovascular events** with ticagrelor.
11. **Prasugrel** should be used cautiously due to **bleeding risk**, especially in older adults or those with a history of stroke.

#### ðŸ”· Tags
#Cardiology #HospitalCare #PatientOver65

#### ðŸ“™ Reference
Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. *JAMA*. 2022;327:662-675. PMID: 35166796 doi:10.1001/jama.2022.0358

#### ðŸ†” Question ID
CVQQQ24003

#### ðŸ•’ Last Updated
January 2025

---

#### ðŸ“– Related Text
MKSAP 19: Cardiovascular Medicine â€” Coronary Artery Disease, Acute Coronary Syndromes, Medical Therapy for Acute Coronary Syndromes

---

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. **All patients with acute coronary syndrome (ACS)** should receive **antithrombotic therapy**, **Î²-blockers**, **ACE inhibitors** (if indicated), **high-intensity statins**, and **antianginal therapy** (e.g., nitrates).
2. **Aspirin** (162â€“325 mg) should be administered **at presentation**, followed by **81â€“162 mg daily** thereafter.
3. **Clopidogrel loading** is recommended in all patients with ACS, regardless of **reperfusion strategy**.
4. **Prasugrel** is indicated only for patients undergoing **PCI**, and should not be given **before coronary angiography**.
5. **Glycoprotein IIb/IIIa inhibitors** are reserved for **select PCI cases** with **large thrombus burden**, **no reflow**, or **slow flow**.
6. **Unfractionated heparin** is preferred in patients undergoing PCI with **kidney dysfunction**, as it allows for **monitoring with activated clotting times**.
7. **Fondaparinux** is not indicated during PCI due to **risk of procedural thrombosis**.
8. **ACE inhibitors** should be initiated within **24 hours** in patients with **heart failure**, **LV dysfunction**, **anterior infarction**, or **diabetes**.
9. **Eplerenone** improves outcomes in **STEMI** patients with **EF â‰¤40%** and **heart failure or diabetes**, especially if started within **1 week** of presentation.
10. **Î²-Blockers** reduce **ventricular arrhythmias**, **angina**, and **mortality** in ACS; they should be initiated **orally** within 24 hours unless contraindicated.
11. **High-intensity statin therapy** reduces **mortality** and **clinical events** after ACS and should be **initiated during hospitalization**.
12. **Oxygen therapy** is only indicated if **oxygen saturation is <90%**, or if there is **dyspnea** or **heart failure**.
13. **Sublingual nitrates** relieve **chest pain** and reduce **sympathetic activation** during ACS; **intravenous nitroglycerin** may be used for **persistent symptoms**, particularly with **hypertension**.
14. **Aspirin desensitization** may be considered in patients with **aspirin allergy** who require treatment for **acute coronary syndrome (ACS)**.
15. **Prasugrel** is **contraindicated** in patients **older than 75 years** or those with a **history of stroke or transient ischemic attack (TIA)**.
16. **Ticagrelor** does **not require first-pass hepatic metabolism** and is **not affected by known genetic polymorphisms**.
17. **Î²-Blockers** with **mortality benefit in left ventricular (LV) systolic dysfunction** include **metoprolol succinate**, **carvedilol**, and **bisoprolol**.
18. **Angiotensin receptor blockers (ARBs)** should **not be used concurrently** with **angiotensin-converting enzyme (ACE) inhibitors** due to overlapping mechanisms and risk of adverse effects.
19. **Eplerenone**, an **aldosterone inhibitor**, is indicated after **ST-elevation myocardial infarction (STEMI)** in patients with **left ventricular ejection fraction (LVEF) â‰¤40%** and either **heart failure** or **diabetes**.
20. **Simvastatin** should be limited to a maximum dose of **20 mg daily** in patients receiving **amlodipine**, due to risk of **drug interaction and myopathy**.
21. **Nitroglycerin** is **contraindicated** in patients with **right ventricular infarction**, **hypertrophic cardiomyopathy (HCM)**, **aortic stenosis (AS)**, or recent use of **phosphodiesterase-5 (PDE-5) inhibitors**.
22. **Nondihydropyridine calcium channel blockers** (e.g., **diltiazem**, **verapamil**) are **contraindicated** in patients with **ST-elevation myocardial infarction (STEMI)** or **left ventricular dysfunction**.
23. **Ranolazine** has **modest QT-prolonging effects** but does **not significantly affect heart rate or blood pressure**.

#### ðŸ’¬ Extra
1. Medical therapy is the foundation of ACS management, regardless of revascularization status.
2. Lower daily aspirin doses are preferred to minimize bleeding risk.
3. Early clopidogrel loading improves platelet inhibition in ACS.
4. Premature prasugrel use before defining PCI eligibility increases bleeding risk without added benefit.
5. These agents are not used routinely and are targeted to PCI complications.
6. Monitoring anticoagulation is critical in patients with impaired renal function.
7. Fondaparinux use during PCI risks catheter thrombosis unless supplemented with heparin.
8. Early RAAS inhibition improves survival and remodeling after MI.
9. Eplerenone should be avoided in patients with hyperkalemia or renal impairment.
10. Contraindications include **hypotension**, **bradycardia**, and **AV block**.
11. Statin preloading before PCI may also reduce procedural complications.
12. Excessive oxygen can increase coronary resistance and infarct size.
13. Tolerance to nitrates develops with prolonged use; dosing adjustments are often needed.
14. Desensitization protocols are typically performed under supervision in settings where aspirin is clinically necessary but previously not tolerated.
15. These populations showed higher bleeding risk in prasugrel trials.
16. This pharmacokinetic profile makes ticagrelor preferable in patients with CYP2C19 variants.
17. These Î²-blockers demonstrated mortality benefit in large clinical trials for heart failure.
18. Dual RAAS blockade increases the risk of **hyperkalemia, hypotension, and renal dysfunction**.
19. Eplerenone's benefit is greatest when started within **7 days of infarction**, particularly in those already on an ACE inhibitor and Î²-blocker.
20. The interaction increases the risk of **statin-induced myopathy**, especially in elderly patients.
21. These conditions heighten sensitivity to nitrates and increase the risk of **severe hypotension**.
22. These agents can exacerbate **bradycardia, conduction delay, or cardiac output reduction** in such patients.
23. Ranolazine is primarily used for **chronic angina** in patients unable to tolerate traditional antianginal agents.

#### ðŸ”· Tags
#Cardiology #ACS #PCI #AntiplateletTherapy #Statins #ACEInhibitor #BetaBlocker #AldosteroneAntagonist #Anticoagulation #Nitrates #OxygenTherapy #RAASInhibition #CalciumChannelBlockers #QTProlongation #DrugInteractions #HeartFailure

---

#### ðŸ§¾ Supplemental Table

<table>
  <caption><strong>Medical Therapy for Acute Coronary Syndromes and Angina</strong></caption>
  <thead>
    <tr>
      <th>Medication</th>
      <th>Drugs in Class</th>
      <th>Dosage</th>
      <th>Indications</th>
      <th>Comments</th>
    </tr>
  </thead>
  <tbody>
    <!-- Antiplatelet Medications -->
    <tr><td colspan="5"><strong>Antiplatelet Medications</strong></td></tr>
    <tr>
      <td><strong>Aspirin</strong></td>
      <td>N/A</td>
      <td>81â€“162 mg/d</td>
      <td>All patients with acute coronary syndrome (ACS), unless intolerant or allergic.<br>All patients with angina.<br>Aspirin desensitization may be considered for patients with allergy.</td>
      <td>Nonenteric formulation recommended for aspirin-naive patients with ACS.</td>
    </tr>
    <tr>
      <td><strong>Clopidogrel</strong></td>
      <td>N/A</td>
      <td>75 mg/d</td>
      <td>P2Y<sub>12</sub> inhibitor in combination with aspirin is indicated in all patients after ACS for at least 1 year.</td>
      <td>Alternative to aspirin for patients with stable coronary artery disease (CAD) and aspirin intolerance or allergy.</td>
    </tr>
    <tr>
      <td><strong>Prasugrel</strong></td>
      <td>N/A</td>
      <td>10 mg/d</td>
      <td>P2Y<sub>12</sub> inhibitor with aspirin indicated after ACS if PCI is performed. Not used before coronary angiography.</td>
      <td>Contraindicated if age >75 or history of stroke/TIA. Adjust to 5 mg/d if weight &lt;60 kg (132 lb).</td>
    </tr>
    <tr>
      <td><strong>Ticagrelor</strong></td>
      <td>N/A</td>
      <td>90 mg twice daily</td>
      <td>P2Y<sub>12</sub> inhibitor in combination with aspirin is indicated in all patients after ACS for at least 1 year.</td>
      <td>Faster onset; no first-pass hepatic metabolism; no known genetic polymorphisms. Higher bleeding risk with aspirin &gt;100 mg.</td>
    </tr>
    <!-- Cardioprotective Medications -->
    <tr><td colspan="5"><strong>Cardioprotective Medications</strong></td></tr>
    <tr>
      <td><strong>Î²-Blockers</strong></td>
      <td>Atenolol, metoprolol, carvedilol, nebivolol, bisoprolol</td>
      <td>Variable</td>
      <td>All patients with prior myocardial infarction (MI) or LV systolic dysfunction (only metoprolol succinate, carvedilol, or bisoprolol).<br>Angina.</td>
      <td>Avoid in cardiogenic shock, hypotension, or conduction disturbances.</td>
    </tr>
    <tr>
      <td><strong>ACE Inhibitors</strong></td>
      <td>Benazepril, captopril, enalapril, fosinopril, perindopril, trandolapril, lisinopril, ramipril, quinapril</td>
      <td>Variable</td>
      <td>All patients with LV systolic dysfunction, hypertension, diabetes mellitus, or kidney disease.</td>
      <td>Especially beneficial in anterior MI.</td>
    </tr>
    <tr>
      <td><strong>Angiotensin Receptor Blockers</strong></td>
      <td>Losartan, valsartan, olmesartan, candesartan, irbesartan, telmisartan</td>
      <td>Variable</td>
      <td>All patients with LV systolic dysfunction, hypertension, diabetes, or kidney disease who are intolerant of ACE inhibitors.</td>
      <td>Should not be combined with ACE inhibitors.</td>
    </tr>
    <tr>
      <td><strong>Aldosterone Inhibitor</strong></td>
      <td>Eplerenone</td>
      <td>25â€“50 mg/d</td>
      <td>Patients with STEMI with LVEF â‰¤40% and either clinical heart failure or diabetes.</td>
      <td>Use caution in chronic kidney disease or hyperkalemia.</td>
    </tr>
    <tr>
      <td><strong>High-Intensity Statins</strong></td>
      <td>Atorvastatin, Rosuvastatin</td>
      <td>Atorvastatin 40â€“80 mg/d<br>Rosuvastatin 20â€“40 mg/d</td>
      <td>All patients with CAD and age â‰¤75 years.</td>
      <td>â€”</td>
    </tr>
    <tr>
      <td><strong>Moderate-Intensity Statins</strong></td>
      <td>Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin</td>
      <td>10â€“40 mg/d depending on agent</td>
      <td>All patients with CAD and age &gt;75 years or who are statin intolerant.</td>
      <td>Simvastatin limited to 20 mg/d if using amlodipine.</td>
    </tr>
    <!-- Antianginal Medications -->
    <tr><td colspan="5"><strong>Antianginal Medications</strong></td></tr>
    <tr>
      <td><strong>Nitroglycerin</strong></td>
      <td>Sublingual, Oral, IV</td>
      <td>Sublingual: 0.4 mg q5min Ã—3<br>IV: 5â€“10 Î¼g/min initial infusion</td>
      <td>Chest pain relief; IV for persistent pain, heart failure, or hypertension.</td>
      <td>Avoid with SBP &lt;90 or â‰¥30 mmHg drop, RV infarction, PDE-5 inhibitors, HCM, or AS.</td>
    </tr>
    <tr>
      <td><strong>Dihydropyridine Calcium Channel Blockers</strong></td>
      <td>Amlodipine</td>
      <td>5â€“10 mg/d</td>
      <td>BP control and angina in hypertensive patients.</td>
      <td>Careful dose titration due to delayed onset.</td>
    </tr>
    <tr>
      <td><strong>Nondihydropyridine Calcium Channel Blockers</strong></td>
      <td>Diltiazem, Verapamil</td>
      <td>Variable</td>
      <td>For patients with NSTE-ACS and angina intolerant to or refractory to Î²-blockers and nitrates.</td>
      <td>Contraindicated in STEMI, heart failure, or AV block.</td>
    </tr>
    <tr>
      <td><strong>Ranolazine</strong></td>
      <td>â€”</td>
      <td>500â€“1000 mg twice daily</td>
      <td>For angina refractory to other therapies. No meaningful HR or BP effect.</td>
      <td>QT-prolonging; reduce dose with CYP3A4 inhibitors. Avoid in cirrhosis.</td>
    </tr>
  </tbody>
</table>
